InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report.
The post Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today? appeared first on InvestorPlace.
More From InvestorPlace